BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 36648946)

  • 1. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
    Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
    JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
    Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
    Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
    Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma.
    Huang Z; Guo Y; Li B; Shen M; Yi Y; Li L; Zhao X; Yang L
    Cancer Gene Ther; 2024 Mar; 31(3):427-438. PubMed ID: 38072971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
    Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
    Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
    Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
    Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
    Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
    Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
    Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
    Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
    Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
    JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
    Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
    J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
    Zhou S; Zhao L; Liang Z; Liu S; Li Y; Liu S; Yang H; Liu M; Xi M
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30717285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.